From Fortune:

The popularity of Novo Nordisk’s weight-loss drugs is expected to surge to $100 billion by 2035. There’s a rise in demand for its drug Wegovy, and surprisingly a willingness among Europeans to pay out of pocket for it. Wegovy brings health benefits other drugs don’t, so their high price means high demand. Novo is in talks with healthcare systems to ease the financial burden on consumers by helping them stagger the payment of Wegovy. There are still supply shortages of Wegovy that Novo is working on easing. As demand for the drugs continues to accelerate, Novo has scrambled to get a grip on their supply. Last year, the Danish company committed to spending $6 billion to bolster production and has plans to expand into Asia. Sales in 2023 were up 31% while year-over-year operating profit climbed 37%.



Read more: Novo Nordisk CEO: ‘Surprised’ about weight-loss drug traction in Europe